The phase III PEONY trial NCT02586025 showed statistically significant improvement in the total pathologic complete response rate for pertuzumab plus trastuzumab plus docetaxel combination as a neoadjuvant treatment of HER2+ early or locally advanced BC in Asian patients [58]. This evidence concerns the gene ERBB2 and breast cancer.